Ko-Jiunn Liu

Dr. Ko-Jiunn Liu


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2014 in Journal of Cellular Physiology
Verified
Journal Article
Open access
PDF file
Chia-Huei LeeChia-Huei Lee
Chia-Huei Lee
JCJeffrey Shu‐Ming Chang
Jeffrey Shu‐Ming Chang
SSShih‐Han Syu
Shih‐Han Syu
TWThian-Sze Wong
Thian-Sze Wong
JCJimmy Yu‐Wai Chan
Jimmy Yu‐Wai Chan
KLKo-Jiunn Liu
Ko-Jiunn Liu
Chronic inflammation, coupled with alcohol, betel quid, and cigarette consumption, is associated with oral squamous cell carcinoma (OSCC). Interleukin‐1 beta (IL‐1β) is a critical mediator of chronic inflammation and implicated in many cancers. In this study, we showed that increased pro‐IL‐1β expression was associated with the severity of oral malignant transformation in a mouse OSCC model induced by 4‐Nitroquinolin‐1‐oxide (4‐NQO) and arecoline, two carcinogens related to tobacco and betel quid, respectively. Using microarray and quantitative PCR assay, we showed that pro‐IL‐1β was upregulated in human OSCC tumors associated with tobacco and betel quid consumption. In a human OSCC cell line TW2.6, we demonstrated nicotine‐derived nitrosamine ketone (NNK) and arecoline stimulated IL‐1β secretion in an inflammasome‐dependent manner. IL‐1β treatment significantly increased the proliferation and dysregulated the Akt signaling pathways of dysplastic oral keratinocytes (DOKs). Using cytokine antibodies and inflammation cytometric bead arrays, we found that DOK and OSCC cells secreted high levels of IL‐6, IL‐8, and growth‐regulated oncogene‐α following IL‐1β stimulation. The conditioned medium of IL‐1β‐treated OSCC cells exerted significant proangiogenic effects. Crucially, IL‐1β increased the invasiveness of OSCC cells through the epithelial‐mesenchymal transition (EMT), characterized by downregulation of E‐cadherin, upregulation of Snail, Slug, and Vimentin, and alterations in morphology. These findings provide novel insights into the mechanism underlying OSCC tumorigenesis. Our study suggested that IL‐1β can be induced by tobacco and betel quid‐related carcinogens, and participates in the early and late stages of oral carcinogenesis by increasing the proliferation of dysplasia oral cells, stimulating oncogenic cytokines, and promoting aggressiveness of OSCC. J. Cell. Physiol. 230: 875–884, 2015. © 2014 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.

18 July 2011 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
PCPei-Min Chen
Pei-Min Chen
MYMen-Luh Yen
Men-Luh Yen
KLKo-Jiunn Liu
Ko-Jiunn Liu
HSHuey-Kang Sytwu
Huey-Kang Sytwu
BYB. Linju Yen
B. Linju Yen
In recent years, a large number of studies have contributed to our understanding of the immunomodulatory mechanisms used by multipotent mesenchymal stem cells (MSCs). Initially isolated from the bone marrow (BM), MSCs have been found in many tissues but the strong immunomodulatory properties are best studied in BM MSCs. The immunomodulatory effects of BM MSCs are wide, extending to T lymphocytes and dendritic cells, and are therapeutically useful for treatment of immune-related diseases including graft-versus-host disease as well as possibly autoimmune diseases. However, BM MSCs are very rare cells and require an invasive procedure for procurement. Recently, MSCs have also been found in fetal-stage embryo-proper and extra-embryonic tissues, and these human fetal MSCs (F-MSCs) have a higher proliferative profile, and are capable of multilineage differentiation as well as exert strong immunomodulatory effects. As such, these F-MSCs can be viewed as alternative sources of MSCs. We review here the current understanding of the mechanisms behind the immunomodulatory properties of BM MSCs and F-MSCs. An increase in our understanding of MSC suppressor mechanisms will offer insights for prevalent clinical use of these versatile adult stem cells in the near future.

19 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KHKuan-Chung Hsiao
Kuan-Chung Hsiao
NSNeng-Yao Shih
Neng-Yao Shih
HFHsun-Lang Fang
Hsun-Lang Fang
THTze-Sing Huang
Tze-Sing Huang
CKChing-Chuan Kuo
Ching-Chuan Kuo
KLKo-Jiunn Liu
Ko-Jiunn Liu
In previous research, we found α-enolase to be inversely correlated with progression-free and overall survival in lung cancer patients and detected α-enolase on the surface of lung cancer cells. Based on these findings, we hypothesized that surface α-enolase has a significant role in cancer metastasis and tested this hypothesis in the current study. We found that α-enolase was co-immunoprecipitated with urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen in lung cancer cells and interacted with these proteins in a cell-free dot blotting assay, which can be interrupted by α-enolase-specific antibody. α-Enolase in lung cancer cells co-localized with these proteins and was present at the site of pericellular degradation of extracellular matrix components. Treatment with antibody against α-enolase in vitro suppressed cell-associated plasminogen and matrix metalloproteinase activation, collagen and gelatin degradation, and cell invasion. Examination of the effect of treatment with shRNA plasmids revealed that down regulation of α-enolase decreases extracellular matrix degradation by and the invasion capacity of lung cancer cells. Adoptive transfer of α-enolase-specific antibody to mice resulted in accumulation of antibody in subcutaneous tumor and inhibited the formation of tumor metastasis in lung and bone. This study demonstrated that surface α-enolase promotes extracellular matrix degradation and invasion of cancer cells and that targeting surface α-enolase is a promising approach to suppress tumor metastasis.

1 September 2015 in Stem Cell Reports
Verified
Journal Article
Open access
WWWei-Bei Wang
Wei-Bei Wang
MYMen-Luh Yen
Men-Luh Yen
KLKo-Jiunn Liu
Ko-Jiunn Liu
PHPei-Ju Hsu
Pei-Ju Hsu
MLMing-Hong Lin
Ming-Hong Lin
BYB. Linju Yen
B. Linju Yen
Multipotent human mesenchymal stromal cells (hMSCs) harbor immunomodulatory properties that are therapeutically relevant. One of the most clinically important populations of leukocytes is the interleukin-17A (IL-17A)-secreting T (Th17) lymphocytes. However, mechanisms of hMSC and Th17 cell interactions are incompletely resolved. We found that, along with Th1 responses, hMSCs strongly suppressed Th17 responses and this required both IL-25--also known as IL--17E-as well as programmed death ligand-1 (PD-L1), a potent cell surface ligand for tolerance induction. Knockdown of IL-25 expression in hMSCs abrogated Th17 suppression in vitro and in vivo. However, IL-25 alone was insufficient to significantly suppress Th17 responses, which also required surface PD-L1 expression. Critically, IL-25 upregulated PD-L1 surface expression through the signaling pathways of JNK and STAT3, with STAT3 found to constitutively occupy the proximal region of the PD-L1 promoter. Our findings demonstrate the complexities of hMSC-mediated Th17 suppression, and highlight the IL-25/STAT3/PD-L1 axis as a candidate therapeutic target.

3 February 2005 in Cancer
Verified
Journal Article
Open access
PDF file
GCGee‐Chen Chang
Gee‐Chen Chang
HLHaw‐Chang Lan
Haw‐Chang Lan
SJShin‐Hun Juang
Shin‐Hun Juang
YWYu‐Chen Wu
Yu‐Chen Wu
HLHui‐Chen Lee
Hui‐Chen Lee
KLKo-Jiunn Liu
Ko-Jiunn Liu
BACKGROUND: The authors conducted a pilot clinical trial to explore the vaccination of patients with late‐stage lung carcinoma with dendritic cells (DCs) pulsed with necrotic tumor cells derived from malignant pleural effusion specimens, and to evaluate the antitumor immune response induced by this therapy.METHODS: Autologous DCs were generated by culturing adherent mononuclear cells with interleukin‐4 and granulocyte‐macrophage–colony‐stimulating factor for 7 days. Day‐7 DCs were cocultured overnight with autologous necrotic tumor cells derived from pleural effusion specimens to allow internalization of tumor antigens. DCs were then treated with tumor necrosis factor‐alpha for 16 hours. The antigen‐loaded DCs were injected into each patient's inguinal lymph nodes under sonographic guidance. Eight patients with late‐stage nonsmall cell lung carcinoma were treated in this manner. Patients were vaccinated once weekly for 4 weeks and then boosted twice biweekly.RESULTS: The authors found that there was no Grade II/III toxicity and autoimmune response in all patients after intranodal injection of the DC vaccine. Minor to moderate increases in T‐cell responses against tumor antigens were observed after DC vaccination in six of eight patients. Five patients had progressive disease. One patient had minor tumor response and two patients had stable disease. The two patients who had longer disease control also had better T‐cell responses.CONCLUSIONS: The results indicated that it was feasible to immunize patients with lung carcinoma intranodally with DCs pulsed with necrotic tumor cells enriched from pleural effusion specimens, and this approach may generate T‐cell responses and provide clinical benefit in some patients. Cancer 2005. © 2005 American Cancer Society.

10 November 2016 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
SLSy‐Jye Leu
Sy‐Jye Leu
YYYi‐Yuan Yang
Yi‐Yuan Yang
HLHsing‐Cheng Liu
Hsing‐Cheng Liu
CCChieh‐Yu Cheng
Chieh‐Yu Cheng
YWYu‐Chen Wu
Yu‐Chen Wu
KLKo-Jiunn Liu
Ko-Jiunn Liu